Latest Conference Coverage

Evobrutinib Significantly Reduces T1 Gd+ Lesions in Relapsing Multiple Sclerosis

This marks the first time a BTK inhibitor showed a clinical proof-of-concept in relapsing MS.

Fernando Dangond, MD, MBA: Evobrutinib for Relapsing Multiple Sclerosis

The Head of Global Clinical Development in Neurology at EMD Serono provided insight into the therapy's performance in phase IIb.

Thomas Leist, MD: Immune Reconstitution Therapy for Multiple Sclerosis

The director of Thomas Jefferson's Comprehensive Multiple Sclerosis Center spoke about the introduction of this treatment method into MS.

Patisiran Shows Sustained Improvements in Disease Progression for hATTR Amyloidosis

Patisiran maintained improvements in mNIS+7 and rapidly halted neurologic disease progression in hATTR amyloidosis.

Robert J. Fox, MD: Neurofilament Light as a Biomarker of Treatment Response

The staff neurologist at Cleveland Clinic’s Mellen Center for Multiple Sclerosis spoke about the current understanding of the biomarker.

Hideki Garren, MD, PhD: The ORATORIO-HAND Trial in PPMS

The Global Head of Neuroimmunology at Genentech discussed the upcoming phase III trial of ocrelizumab while on-site at ECTRIMS 2018.

Cladribine Tablets Safety Profile Reaffirmed With Long-Term Data

An updated safety analysis of the therapy in patients with relapsing MS, up to 10 years, has shown no new safety signals.

Subcutaneous Immunoglobulin Effective Alternative to Intravenous for Myasthenia Gravis

Subcutaneous immunoglobulin is an effective and well-tolerated alternative to intravenous immunoglobulin for myasthenia gravis.

Eculizumab's Myasthenia Gravis Benefits Sustained in Long-Term Extension Study

Eculizumab showed sustained activity and tolerability through 3 years for generalized myasthenia gravis.

Richard Rudick, MD: Using Data to Personalize MS Care

The vice president of Medical Research at Biogen spoke about the intersection between high-quality data utilization and individualized medicine in multiple sclerosis.

John Corboy, MD: Taking Patients Off Of Disease-Modifying Therapy

The professor of neurology at the University of Colorado posited that if certain criteria are met, it could be appropriate to take patients with multiple sclerosis off of DMT.

Earlier Treatment With Ocrelizumab Shows Favorable Results in Relapsing, Primary Progressive MS

Data from multiple open-label extension trials have suggested that the therapy is more beneficial with earlier initiation compared to interferon ß-1a.

Eva Winnebeck, PhD: Temporal Dynamics of Sleep

The postdoctoral scientist spoke about an actimetry-based method studying the clinical relevance of temporal dynamics of sleep to make the dynamics easily quantifiable in everyday context.

Johan Verbraecken, MD, PhD: Challenges in Conducting Clinical Trials in OSA

The medical coordinator of the Multidisciplinary Sleep-Wake Disorders Center at Antwerp University Hospital spoke about how to address some of the issues faced in OSA treatment development.

Tessa Blanken, MSc: Identification of Robust, Clinically Relevant Insomnia Subtypes

The identification of the subtypes allows future studies to target homogeneous subtype samples, resolve inconsistencies, personalize treatment and utilize preventive interventions.

Danny Eckert, PhD: Pharmacotherapies Reducing OSA Severity

Proof-of-concept studies using a targeted phenotypic approach to reduce obstructive sleep apnea severity are showing exciting results.

Danny Eckert, PhD: Unlocking New Targets For Pharmacological Therapy In OSA

The identification of 3 key non-anatomical contributors to OSA has unlocked new potential pharmacotherapies, a major advance for the field.

Jan Hedner, MD, PhD: Current Therapeutic Landscape of Obstructive Sleep Apnea

Recent research has identified novel potential pathophysiological mechanisms that could potentially serve to subclassify various phenotypes in obstructive sleep apnea.

Eva Winnebeck, PhD: Movement Rhythms During Sleep

The actimetry-based method allows for easily quantifiable sleep dynamics in real life context, enabling large-scale clinical studies to investigate the complex temporal dynamics of sleep.

Krista Lanctot, PhD: Managing Patients with Agitation

Lanctôt advised ruling out any possible underlying medical conditions that could be causing it, including pain, as well as starting with any non-pharmacologic interventions.

Geert Mayer, MD: Safety, Efficacy of Solriamfetol for Excessive Sleepiness In Narcolepsy, OSA

Long-term maintenance of efficacy was demonstrated with solriamfetol for treatment of excessive sleepiness with narcolepsy or obstructive sleep apnea.

Irina Pikuleva, PhD: Activating CYP46A1 with Efavirenz

The Carl F. Asseff Professor of Ophthalmology and the Director of the Visual Sciences Research Center at Case Western Reserve University spoke about the beginnings of her work with efavirenz.

Geert Mayer, MD: Solriamfetol As Potential Therapy for Excessive Sleepiness in Narcolepsy, Obstructive Sleep Apnea

The neurologist and sleep specialist spoke about data from one of many studies investigating solriamfetol for treatment of narcolepsy and obstructive sleep apnea with remaining excessive daytime sleepiness.

Paul Newhouse, MD: Attacking Different Targets in Alzheimer

The Jim Turner Chair in Cognitive Disorders at the Vanderbilt University School of Medicine shared his feelings on the early phase treatments.

Daphne Chylinski: Arousals During Sleep Are Strongly Linked to Alzheimer Disease Pathophysiology

Chylinski spoke about the relationship between the increased number of arousals during sleep and the pathogenesis of Alzheimer disease.

Howard Fillit, MD: The Importance of Biomarkers for Alzheimer Disease

Fillit spoke about remaining need for additional biomarkers in Alzheimer, and what has been developed in recent years.

Krista Lanctot, PhD: Addressing Alzheimer Disease Agitation

The psychiatry and pharmacology professor at the University of Toronto and senior scientist at Sunnybrook Research Institute spoke about the use of cannabinoids to treat agitation in Alzheimer.

Irina Pikuleva, PhD: Using Efavirenz in Alzheimer Disease

The Carl F. Asseff Professor of Ophthalmology and the Director of the Visual Sciences Research Center at Case Western Reserve University further discussed the trial of efavirenz in AD.

Eugenia Trushina, PhD: Communication and Learning Through Collaboration

For the associate professor of neurology, learning, listening, and collaborating are the keys to improving the field of care.

Paul Newhouse, MD: Exploring VU319 in Alzheimer Disease

The Jim Turner Chair in Cognitive Disorders at the Vanderbilt University School of Medicine explained more about the molecule and the subsequent trial of it.